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Defects in cellular DNA repair processes have been linked to genome instability, heritable 
cancers, and premature aging syndromes. Yet defects in some repair processes manifest 
themselves primarily in neuronal tissues. This review focuses on studies defining the molec-
ular defects associated with several human neurological disorders, particularly ataxia with 
oculomotor apraxia 1 (AOA1) and spinocerebellar ataxia with axonal neuropathy 1 (SCAN1). 
A picture is emerging to suggest that brain cells, due to their nonproliferative nature, may 
be particularly prone to the progressive accumulation of unrepaired DNA lesions.The link between defective DNA repair and cancer was 
first established by James E. Cleaver, who recognized 
that fibroblasts grown in culture from individuals with the 
hereditary cancer-related disease xeroderma pigmento-
sum (XP) were defective in the repair of DNA damage 
induced by UV light (Cleaver, 1968). Most forms of this 
disease are caused by mutations in genes involved in 
nucleotide excision repair, a repair pathway that removes 
UV light-induced DNA lesions. Consequently, XP patients 
are extremely photosensitive and need to be shielded 
from sunlight exposure to avoid skin cancer. As Cleaver 
later stated “XP demonstrated that human cancer was 
a genetic disease that could be understood in terms of 
damage and repair to human genes.” His original study 
of XP also connected DNA repair with neurodegenera-
tion, as it “involved two types of clinical circumstances, 
both with reduced repair, one with skin cancer, and the 
other with cancer and neurodegeneration.” About 20% 
of XP patients suffer from neurological disease char-
acterized by microcephaly (in which the circumference 
of the head is smaller than average), progressive neu-
rodegeneration involving peripheral neuropathy, loss of 
reflexes, ataxia, and dementia. The nucleotide excision 
repair-associated disorders Cockayne syndrome (CS) 
and trichothiodystrophy (TTD) have overlapping clinical 
features with XP including neurological defects but are 
not characterized by an increased susceptibility to can-
cer (Table 1) (Lehmann, 2003).
Often the occurrence and severity of neurological 
defects in XP patients correlates with UV sensitivity, 
suggesting that the nucleotide excision repair defect is 
directly responsible for neuronal cell death. But as neu-
ronal cells are never exposed to sunlight, the possibility 
of UV damage is unlikely. Instead, it appears that endog-
enous damage caused by reactive oxygen species, a 
consequence of the high rate of oxidative metabolism 
in the brain, is the underlying cause of neuropathogenic DNA lesions. DNA lesions induced by reactive oxygen 
species have the potential to block transcription by RNA 
polymerase II, and their accumulation in repair-defec-
tive individuals may cause neuronal cell death, either 
by progressively depriving the cell of vital transcripts or 
through apoptosis (Ljungman and Lane, 2004). However, 
a direct correlation between such unrepaired oxidative 
DNA damage and the neurological implications in XP, 
CS, and TTD has not been obtained, so this relationship 
remains open to question and illustrates the difficulty 
in determining the causative lesion in any of the DNA 
repair-deficient neurological diseases. Here we discuss 
the molecular defects associated with several human 
neurological disorders, particularly ataxia telangiectasia 
(A-T), ataxia with oculomotor apraxia 1 (AOA1), and spi-
nocerebellar ataxia with axonal neuropathy 1 (SCAN1).
A-T as a Model for Neurodegenerative Disease 
Linked to Defects in DNA Repair
A-T provides a well-characterized example of the rela-
tionships that exist between repair defects and neuro-
degenerative disease (Table 1). This childhood disease 
is characterized by progressive impairment of gait and 
speech, oculomotor apraxia (inability to move the eyes 
from one object to another), oculocutaneous telangiec-
tasia (dilated blood vessels), cerebellar atrophy, sterility, 
and radiosensitivity (McKinnon, 2004). Approximately 
10%–15% of A-T patients develop cancer, most fre-
quently acute lymphocytic leukemia and lymphoma. The 
prognosis for survival is poor, and individuals with this 
disease usually die in their teens.
The pleiotropic clinical manifestations associated with 
mutations in the ATM gene (which is responsible for A-T) 
reflect the critical roles played by ATM, a protein kinase 
required for the cellular response to DNA double-strand 
breaks (DSBs) (Shiloh, 1997). In response to DSB forma-
tion, ATM kinase is activated and elicits a coordinated Cell 130, September 21, 2007 ©2007 Elsevier Inc. 991
Table 1. DNA-Repair Deficiency and Neurodegeneration
Syndrome Disease gene Neurological implications Other
Nucleotide excision repair
Xeroderma pigmentosum (XP) XPA, XPB, XPD,  
XPF, XPG, XPV
microcephaly, progressive 
neurodegeneration
neoplasm of the skin and eyes
Cockayne syndrome (CS) XPB, XPD, XPG,  
CSA, CSB
microcephaly, progressive 
neurodegeneration
dwarfism
Trichothiodystrophy (TTD) XPB, XPD,  
TFB5/TTD-A
microcephaly brittle hair
DNA damage response/DSB repair
Ataxia telangiectasia (A-T) ATM ataxia, progressive 
 neurodegeneration
immunological implications, 
 lymphoid malignancy
Ataxia telangiectasia-like disorder 
(ATLD)
MRE11 ataxia, progressive 
 neurodegeneration
immunological implications, 
 lymphoid malignancy
Nijmegen breakage syndrome (NBS) NBS1 microcephaly immunological implications, 
 lymphoid malignancy, short stature
ATR-Seckel syndrome (ATR-Seckel) ATR microcephaly dwarfism
Primary microcephaly 1 (MCPH1) MCPH1/BRIT1 microcephaly
LIG4 syndrome LIG4 microcephaly immunodeficiency, lymphoid 
 malignancy, developmental and 
growth delay
Immunodeficiency with microcephaly Cernunnos/XLF microcephaly immunodeficiency, lymphoid 
 malignancy
SSB repair
Ataxia with oculomotor apraxia 1 
(AOA1)
Aprataxin ataxia, progressive 
 neurodegeneration, 
 oculomotor apraxia
hypoalbuminemia,  
hypercholesterolemia
Spinocerebellar ataxia with axonal 
neuropathy (SCAN1)
Tyrosyl-DNA  
phosphodiesterase 1
ataxia, sensory loss hypoalbuminemia,  
hypercholesterolemia
Syndromes are classified according to the defects in nucleotide excision repair, the DNA-damage response/DNA double-strand 
break repair, and DNA single-strand break repair. Note that defects in single-strand break repair primarily affect the nervous sys-
tem. The indicated clinical implications are intended to give an overview and are not comprehensive.damage response that ensures genomic stability by 
integrating DNA repair with progression through the cell 
cycle, gene expression, chromatin remodeling, and pro-
grammed cell death. Chromosomal DSBs are potentially 
one of the most dangerous forms of DNA damage that, if 
left unrepaired, can result in chromosomal aberrations, 
deletions, or translocations. They can also pose problems 
during mitosis, as intact chromosomes are required for 
proper chromosome segregation. Consequently, defects 
in DSB repair are linked to cell death and tumorigenesis 
(Burma et al., 2006). ATM is also involved in immune cell 
maturation, which proceeds through physiological DSBs 
and gene rearrangements, as indicated by the immuno-
logical implications associated with A-T (Reina-San-Mar-
tin et al., 2004; Xu et al., 1996).
The pronounced neuropathology of individuals with A-
T, however, is more difficult to explain. Why should the 
nervous system develop normally and then suffer a tis-
sue-specific loss of viability once it has achieved matu-
rity? An important clue to this question was obtained 
when it was shown that mice lacking the Atm gene lose 
the ability to induce apoptosis in differentiating neuro-
nal cells, but not in proliferating precursor neuroblasts, 992 Cell 130, September 21, 2007 ©2007 Elsevier Inc.in response to DNA damage induced by ionizing radia-
tion (Herzog et al., 1998; McConnell et al., 2004). These 
results indicate that ATM may be required for the elimi-
nation of damaged neuronal cells during development 
in order to prevent them from being integrated into a 
weakened nervous system. There is also some evi-
dence to support the view that ATM deficiency is linked 
to increased oxidative stress within the cerebellum, the 
area of the central nervous system most affected in A-T 
patients (Barlow et al., 1999; Barzilai et al., 2002; Kamsler 
et al., 2001). These results may indicate that the kinase 
activity of ATM is required to minimize the progressive 
accumulation of oxidative DNA lesions.
Other Repair-Defective Neurological Disorders
The complex neurological and extraneurological pheno-
types seen with A-T are not so unusual. Indeed, they are 
rather typical of diseases caused by defects in proteins 
that play important roles in the DNA-damage response 
and/or are directly involved in the repair of DSBs (Table 
1). For example, A-T-like disorder (ATLD) and Nijme-
gen breakage syndrome (NBS) are very similar to A-T, 
although NBS is a developmental disorder character-
ized by microcephaly rather than progressive neurode-
generation. These diseases are caused by hypomorphic 
mutations in MRE11 and NBS1, respectively. The prod-
ucts of the MRE11 and NBS1 genes associate with 
RAD50 protein to form the MRE11/RAD50/NBS1 com-
plex that is important for sensing DSBs and activation of 
ATM kinase activity. This relationship with ATM provides 
a molecular basis for the phenotypic features shared 
with A-T. Similarly, ATR-Seckel syndrome, characterized 
by growth defects, microcephaly, and mental retarda-
tion, is caused by a hypomorphic mutation in the ATR 
gene, which encodes a kinase required for the cellular 
response to replicative stress. This response involves 
cell-cycle arrest and replication fork stabilization, which 
ultimately allows complete progression through S phase 
(Petermann and Caldecott, 2006). However, although the 
ATR-Seckel syndrome phenotype suggests an exquisite 
sensitivity of neuronal cells to DNA damage resulting 
from replication fork collapse and breakage, the pre-
cise determinants for cell-type specificity are unclear. 
Another microcephaly disorder, primary microcephaly 
1 (MCPH1), was recently linked to ATR by observations 
showing that hypomorphic mutations in the disease gene 
MCPH1/BRIT1 cause defects in ATR signaling (O’Driscoll 
et al., 2006). Similarly, microcephaly associated with 
NBS1 mutation may be related to a downstream func-
tion of NBS1 in ATR signaling, one that is quite distinct 
from its DNA-damage sensor function in ATM signaling 
(Stiff et al., 2005).
Mutations in genes that encode proteins directly 
involved in DSB repair have also been linked to micro-
cephaly. There are two primary mechanisms of DSB 
repair in vertebrates—homologous recombination and 
nonhomologous end joining. DSB repair by nonhomolo-
gous end joining is mediated by a number of proteins, 
including Ku70/Ku80, DNA-PKcs, XLF, and DNA ligase 
IV/XRCC4 complex, and occurs by a relatively simple 
end splicing and ligation reaction. Inactivation of non-
homologous end joining in the mouse—through disrup-
tion of DNA ligase IV/XRCC4 or XLF (also known as Cer-
nunnos)—can lead to defects in neurogenesis or brain 
tumours (Barnes et al., 1998; Buck et al., 2006; Gao et 
al., 1998; Lee et al., 2000; O’Driscoll et al., 2001). For 
example, the DNA ligase IV-deficient mouse shows mas-
sive cell death in the developing nervous system and 
embryonic lethality. Cell death may be a reflection of the 
propensity of damaged neuronal cells to induce apop-
tosis rather than to mature into differentiated neurons. 
Such a cellular program might be reasonable because 
cell loss can be compensated for during neurogenesis, 
but unfortunately, this is not the case with the mature 
nervous system. DSB repair can also be promoted by 
RAD51-mediated homologous recombination, which 
involves interactions between the broken DNA and the 
sister chromatid (West, 2003). RAD51 is controlled by 
BRCA2, mutations in which lead to a predisposition to 
breast and ovarian cancers (Venkitaraman, 2004). In the 
mouse, mutations in RAD51 or BRCA2 are embryonic lethal (Lim and Hasty, 1996; Sharan et al., 1997), but it 
has been possible to determine the effects of BRCA2 
loss in the brain by conditional gene inactivation. This 
analysis uncovered a new link with neurodegeneration, 
as BRCA2 inactivation resulted in microcephaly asso-
ciated with defects in neurogenesis, particularly during 
cerebellar development (Frappart et al., 2007).
New Insights into the Neurodegenerative Diseases 
AOA1 and SCAN1
The complex and multisystemic effects caused by defects 
in basic DNA-repair mechanisms are now well character-
ized. Research over many years has shown that neuro-
degenerative defects are often associated with repair 
syndromes, but it has been very difficult to establish the 
precise causative links between these processes. How-
ever, recent research on the neurodegenerative disorders 
ataxia with oculomotor apraxia 1 (AOA1) and spinocere-
bellar ataxia with axonal neuropathy 1 (SCAN1), which are 
caused by dysfunction of Aprataxin (APTX) and tyrosyl-
DNA phosphodiesterase 1 (TDP1), respectively, sheds 
new light on the underlying basis of DNA repair-associ-
ated neurodegeneration. AOA1 and SCAN1 are autoso-
mal recessive cerebellar ataxias, but in contrast to A-T, 
their phenotypes are very much restricted to the nervous 
system. Recent findings indicate that neuronal cell death 
in AOA1 and SCAN1 is primarily due to the specific proof-
reading roles that Aprataxin and TDP1 play in the repair 
of DNA single-strand breaks (SSBs). This unprecedented 
correlation between molecular defect and neuron-spe-
cific impact may provide the missing link that allows us to 
begin to understand the relationship between neurode-
generation and defective DNA repair.
Aprataxin and AOA1
In 1988, the neurological disorder “ataxia with oculomo-
tor apraxia” was defined as a new syndrome. Although 
the neurological symptoms were similar to those exhib-
ited by patients with A-T, the absence of multisystemic 
involvement indicated that this was a syndrome distinct 
from A-T (Aicardi et al., 1988). Genetic studies subse-
quently revealed nonallelic heterogeneity in AOA, and 
two subgroups, named AOA1 (Date et al., 2001; Moreira 
et al., 2001) and AOA2 (Moreira et al., 2004), were 
described. The genetic defect associated with AOA1 
maps to chromosome 9p13 (APTX, encoding Aprataxin) 
and that of AOA2 maps to 9q34 (SETX, encoding Sena-
taxin, a homolog of a superfamily 1 RNA helicase known 
as Sen1 in yeast).
AOA1 is characterized by cerebellar atrophy and senso-
rimotor neuropathy. Clinical manifestations include distur-
bances in motor coordination from an early age (2–6 years), 
oculomotor apraxia, loss of reflexes, and progressive dis-
ability leading to confinement to a wheelchair in adolescent 
life (Le Ber et al., 2003). Hypoalbuminemia (low blood albu-
min) and hypercholesterolemia (high levels of cholesterol in 
blood) are also common symptoms. AOA1 occurs in many 
ethnic groups but is most frequent in Japan and Portugal.Cell 130, September 21, 2007 ©2007 Elsevier Inc. 993
Figure 1. Features of Aprataxin and 
XRCC1
(Top panel) The three-domain structure of hu-
man Aprataxin (APTX) showing the FHA (fork-
head-associated), HIT (histidine-triad), and 
ZnF (zinc-finger) domains. The HIT domain 
contains the catalytic histidine triad, inter-
spersed with hydrophobic amino acids (φ). 
Mutations associated with AOA1 mostly map 
directly to or immediately downstream of the 
HIT domain (red lines). Critical residues are in-
dicated (yellow lines), and those in bold font 
are essential for domain function.
(Bottom panel) The three-domain structure 
of XRCC1 showing the N-terminal domain 
(NTD) and two BRCT domains. XRCC1 in-
teracts with Aprataxin, DNA ligase III (LigIII), 
PNKP, Aprataxin and PNKP-like factor (APLF), 
DNA polymerase β (Polβ), APE1, PARP1 and 
PARP2, and indirectly with TDP1. Aprataxin, 
PNKP, and possibly APLF interact with the re-
gion between the BRCTI and BRCTII domains, 
where the CK2 phosphorylation sites are lo-
cated (indicated by yellow lines). Sites classi-
fied as primary CK2 phosphorylation sites are 
in roman font, others in italics. Solid lines in-
dicate experimental evidence for in vivo phos-
phorylation, and sites critical for Aprataxin 
binding are shown in bold.Aprataxin is a 342 amino acid protein that localizes to 
the nucleus and nucleolus (Clements et al., 2004; Date et 
al., 2001; Gueven et al., 2004; Moreira et al., 2001). It has 
three distinct domains: an N-terminal forkhead-associ-
ated (FHA) domain, a central histidine triad (HIT) domain, 
and a C2H2 zinc-finger (ZnF) domain at the C terminus 
(Figure 1). Detailed examination of these three domains 
has helped elucidate the repair role played by Aprataxin 
and its relevance for maintaining genome integrity in 
neuronal tissues.
Guilt by Association: Aprataxin Interacts with 
DNA-Repair Proteins
FHA domains represent phosphoprotein-binding mod-
ules and are found in a wide variety of prokaryotic and 
eukaryotic proteins (Durocher and Jackson, 2002). The 
FHA domain of Aprataxin is embedded in a region of 
?100 amino acids that shares homology with the N-ter-
minal region of human polynucleotide kinase 3′ phos-
phatase (PNKP) (Caldecott, 2003a; Moreira et al., 2001). 
Within this region, residues R29 and S41 in Aprataxin 
(Figure 1) and R35 and S47 in PNKP correspond to the 
highly conserved phosphothreonine-binding residues 
found in other FHA domains.
The presence of closely related FHA domains in 
Aprataxin and PNKP implies that both proteins are 
likely to interact with the same phosphorylated protein 
targets. PNKP’s targets have been identified as XRCC1 
and XRCC4, subunits of the DNA ligase complexes 
that promote SSB repair and DSB repair, respectively 
(Chappell et al., 2002; Koch et al., 2004; Whitehouse 
et al., 2001). PNKP is a very useful enzyme to have 
around during DNA break repair, as it possesses 5′-
DNA kinase and 3′-DNA phosphatase activities that 994 Cell 130, September 21, 2007 ©2007 Elsevier Inc.can convert blocked 3′ phosphate and 5′-hydroxyl ter-
mini into termini that can be ligated (Jilani et al., 1999; 
Karimi-Busheri et al., 1999).
Aprataxin also interacts with XRCC1 and XRCC4 (Cle-
ments et al., 2004; Luo et al., 2004). Aprataxin-XRCC1 
interactions are mediated by the FHA domain of Aprataxin 
and are abrogated by mutation of the conserved R29 
residue (Clements et al., 2004; Gueven et al., 2004; Sano 
et al., 2004) or the C-terminal region of XRCC1 involving 
phosphoresidues S518, T519, and T523 (Figure 1) (Luo 
et al., 2004). These amino acids are part of a cluster of 
CK2 phosphorylation sites in the linker region between 
the BRCTI and BRCTII domains in XRCC1 and are also 
critical for PNKP binding (Loizou et al., 2004). In total, 
the cluster contains 13 serine and threonine residues 
that have the potential to be phosphorylated by protein 
kinase CK2 (Figure 1).
Because Aprataxin and PNKP target the same region 
of XRCC1, it is thought that the associations of these 
proteins with XRCC1 are mutually exclusive. Consistent 
with this proposal, XRCC1 immunoprecipitates contain 
both Aprataxin and PNKP, whereas an Aprataxin immu-
noprecipitate contains XRCC1 but not PNKP (Luo et al., 
2004). These results indicate that XRCC1 is the limiting 
factor for complex formation, which may be regulated by 
alternative CK2 phosphorylation patterns at the BRCTI/
BRCTII linker region. Complexes between XRCC1 and 
Aprataxin or PNKP have been detected in extracts pre-
pared from damaged and undamaged cells, sugges-
tive of constitutive associations between these proteins 
(Clements et al., 2004; Loizou et al., 2004; Luo et al., 
2004). This might be expected as the CK2 protein kinase 
is constitutively active and will constantly be present for 
Figure 2. Involvement of Aprataxin in 
Single- and Double-Strand Break Repair
(A and B) Complexes involved in single-strand 
break (SSB) and double-strand break (DSB) repair, 
respectively.
(C) SSBs resulting from sugar damage or enzymat-
ic cleavage are detected by PARP1 and PARP2. 
Binding of the break activates PARP for auto-
poly(ADP-ribosylation), thereby signaling to other 
DNA-repair proteins. PARP recruits XRCC1, setting 
up a molecular scaffold for SSB repair, which is co-
ordinated through interactions of individual repair 
enzymes with XRCC1. DNA end-processing fac-
tors such as PNKP and TDP1 restore conventional 
5′-phosphate and 3′-hydroxyl termini at the break 
site. Most gapped single-strand breaks are then 
reduced to a nick by the action of DNA polymerase 
β, before being sealed by DNA ligase III. Aprataxin 
interacts with XRCC1 and may participate in DNA 
end processing of abortive ligation events. Red as-
terisks indicate unconventional DNA termini.
(D) DSB repair by the nonhomologous end-join-
ing pathway is initiated by the DNA-dependent 
protein kinase (DNA-PK), consisting of the 
Ku70/80 heterodimer and the DNA-PK catalytic 
subunit (DNA-PKcs). Depending on the nature 
of the break, PNKP, Artemis, and other DNA 
end-processing factors participate in the repair 
reaction. DNA polymerases µ and λ are impli-
cated in filling remaining gaps, before DNA-PK 
recruits the XRCC4/DNA ligase IV complex for 
break ligation. Aprataxin may be present at this 
stage of the DSB repair reaction by interaction 
with XRCC4. Red asterisks indicate unconven-
tional DNA termini.phosphorylation of the BRCTI/BRCTII linker region of 
XRCC1. Taken together, these experiments suggest that 
there are two distinct complexes: XRCC1/DNA ligase 
III/APTX and XRCC1/DNA ligase III/PNKP. These asso-
ciations place Aprataxin, like PNKP, in the context of 
the multiprotein SSB repair machinery, in which XRCC1 
acts as a molecular scaffold that is required for effective 
repair (Figures 2A and 2C) (Caldecott, 2003b).
As mentioned above, Aprataxin also associates with 
XRCC4 through its FHA domain, and the formation of 
the XRCC4/DNA ligase IV/APTX complex is again con-
stitutive (Clements et al., 2004). Given that DNA ligase IV 
and XRCC4 are required for nonhomologous end joining 
(Burma et al., 2006), these interactions indicate a role for 
Aprataxin in DSB repair (Figures 2B and 2D). Whether 
the binding of Aprataxin to XRCC4 occurs competitively 
with PNKP is presently unknown.
Aprataxin also interacts with PARP1 and PCNA, which 
is reasonable given that PARP1 acts as a nick sensor 
in SSB repair (Figure 2C), whereas PCNA plays a scaf-
folding role in a subset of SSB repair events (Gueven 
et al., 2004; Hirano et al., 2007). However, these may 
be mediated through XRCC1 because interactions 
between PARP1 and Aprataxin have not been seen in 
yeast two-hybrid assays, and the association of PCNA 
with Aprataxin is diminished by N-terminal deletions of 
Aprataxin that affect XRCC1 binding (Date et al., 2004).
Recently, a third protein that has an FHA domain 
related to that of Aprataxin and PNKP was described (Bekker-Jensen et al., 2007; Iles et al., 2007; Kanno et al., 
2007). This protein, called APLF (Aprataxin and PNKP-
like factor), or PALF (PNKP and Aprataxin-like FHA pro-
tein), or XIP1 (XRCC1-interacting protein) interacts with 
XRCC1 and XRCC4 and plays an unknown role in DNA 
strand-break repair.
Hitting the Target: A Role for Aprataxin in DNA-
Break Repair
Aprataxin’s interactions with a defined set of DNA repair 
proteins, together with the presence of a putative zinc-
finger DNA-binding domain, indicates a direct involve-
ment in DNA maintenance. However, it was several years 
before any DNA repair-related biochemical functions for 
Aprataxin were discovered.
Most mutations found in AOA1 patients (shown in red 
in Figure 1) map to the catalytic HIT domain of Aprataxin. 
This domain contains a characteristic HφHφHφφ sequence 
motif (where φ denotes a hydrophobic residue), which 
is found in the histidine triad superfamily of nucleotide 
hydrolases and transferases, which act on the α-phos-
phate of ribonucleotides (Brenner, 2002). There are 
several branches in the HIT superfamily, defined as the 
histidine triad nucleotide-binding proteins (HINT), the 
fragile histidine triad gene proteins (FHIT), the galactose-
1-phosphate uridylyltransferases (GALT), and the mRNA 
decapping scavenger proteins (DCPS) (Figure S1).
In early studies, Aprataxin was shown to exhibit nucle-
otide hydrolase activity with diadenosine polyphos-
phates (ApnA) and synthetic dinucleoside polyphos-Cell 130, September 21, 2007 ©2007 Elsevier Inc. 995
phate analogs, which represent model substrates for 
the FHIT-branch proteins of the HIT superfamily. It was 
therefore assumed to be a member of the FHIT branch 
of the family (Date et al., 2001; Hirano et al., 2004). How-
ever, when the activity of Aprataxin was tested on phos-
phoramides, it was found to have greater activity with 
AMP lysine than with ApppA and AppppA, leading to 
the suggestion that Aprataxin is really a HINT-like AMP-996 Cell 130, September 21, 2007 ©2007 Elsevier Inc.lysine hydrolase (Seidle et al., 2005). These observations 
supported earlier suggestions that Aprataxin might act 
to deadenylate protein targets involved in DNA repair 
(Caldecott, 2003a).
Importantly, these studies confirmed the catalytic 
potential of the HIT domain of Aprataxin and dem-
onstrated that disease-related mutations resulted in 
severely reduced catalytic activity (Hirano et al., 2004; 
Seidle et al., 2005). However, it was a concern that the 
catalytic activity of Aprataxin was one to two orders of 
magnitude lower than those reported for rabbit HINT on 
AMP lysine (Bieganowski et al., 2002) or human FHIT 
on ApppA (Lima et al., 1997). Doubts were arising as to 
whether ApnA and AMP lysine were physiological sub-
strates for Aprataxin.
The tide turned in another direction when Martin 
Lavin’s group observed that Aprataxin could bind DNA. 
They also found that the presence of DNA markedly 
reduced the nucleotide hydrolase activity with AppppA, 
suggestive of competitive inhibition (Kijas et al., 2006). 
Subsequently, it was shown that Aprataxin acts upon 
a novel substrate, namely DNA adenylates that result 
from abortive DNA ligation events (Ahel et al., 2006). 
The interaction of Aprataxin with XRCC1/DNA ligase III 
and XRCC4/DNA ligase IV complexes provided the clue 
to the discovery of Aprataxin’s function. The reaction 
mechanism for ATP-dependent DNA ligation involves 
formation of a nucleotidylated DNA intermediate, spe-
cifically a 5′-DNA adenylate (Figure 3). In the first step 
of the reaction, DNA ligase interacts with ATP to form 
a complex in which AMP becomes covalently bound to 
the active site lysine. The adenylated ligase then trans-
fers the adenylyl group to the 5′ phosphate at the nick 
to form a 5′-DNA adenylate. Finally, to complete the 
reaction, ligase catalyses attack of the 3′ hydroxyl at the 
nick on the activated 5′ phosphate, leading to the forma-
tion of a phosphodiester bond that seals the nick, and 
releases AMP. Many nicks in DNA, however, do not pos-
Figure 3. Resolution of Abortive DNA Ligation Intermediates 
by Aprataxin
(Inset) ATP-dependent DNA ligases catalyze ligation through three 
distinct reaction steps: (1) cleavage of ATP into AMP and pyrophos-
phate and transfer of the AMP moiety to its active site lysine; (2) at-
tack of the 5′ phosphate at the break site on the activated phosphoryl 
group of the AMP at the active site of the ligase; (3) attack of the 3′ 
hydroxyl of the SSB on the adenylated 5′ phosphate, which restores 
the continuity of the DNA backbone and releases AMP.
(Top panel) The action of DNA ligase at a gapped SSB with uncon-
ventional DNA termini can lead to abortive ligation. A typical oxidative 
SSB contains phosphates at both the 5′ and the 3′ end (indicated by 
an arrowhead) and a one-nucleotide gap (indicated by the dotted out-
line of a missing nucleotide). At such a dirty break the DNA ligase can 
catalyze steps 1 and 2 of the ligation reaction but then aborts, leading 
to the formation of a 5′-DNA adenylate.
(Lower panel) Aprataxin resolves 5′ adenylates by releasing AMP 
and restoring the 5′ terminus of the SSB. This proofreading DNA-
repair function probably proceeds through two catalytic steps: (1) 
attack of the adenylated 5′ phosphate leading to release of the de-
adenylated DNA and transfer of the AMP onto Aprataxin’s active 
site histidine triad, and (2) hydrolysis of the 5′ phosphohistidine to 
release AMP and restore Aprataxin. Subsequently, the SSB can be 
processed and ligated.
sess conventional DNA termini, and unusual termini are 
known to perturb DNA ligation reactions. For example, 
oxygen radical attack at the DNA backbone can lead 
to sugar fragmentation that causes the formation of an 
SSB and the loss of a base. In this case, the SSB will be 
left with phosphate groups at both the 5′ and 3′ termini. 
Such “dirty breaks” are common because the cellular 
DNA is constantly exposed to reactive oxygen species 
that arise as byproducts of oxidative phosphorylation 
in mitochondria. DNA ligase III erroneously recognizes 
dirty breaks as substrates and initiates the ligation pro-
cess but cannot complete it due to the unconventional 
phosphate at the 3′ terminus. Instead, abortive ligation 
leads to the formation of persistent 5′-DNA adenylates 
that could themselves be a serious DNA adduct. This 
concept gave rise to the idea that Aprataxin could act as 
a proofreading enzyme for abortive ligation events, and 
subsequent biochemical studies showed that Aprataxin 
exhibited a novel 5′-DNA deadenylation activity that was 
several orders of magnitude greater than that observed 
with the dinucleoside polyphosphate and AMP-lysine 
substrates (Ahel et al., 2006). The action of Aprataxin 
unblocks the DNA 5′ end to restore a conventional 5′-
phosphate terminus, which can again serve as a site 
for ligation (Figure 3). Thus, Aprataxin gives other DNA 
repair proteins a second chance to process unligatable 
breaks and to reinitiate DNA ligation.
The relationship between Aprataxin’s deadenylation 
activity and AOA1 was demonstrated using extracts 
prepared from an Aptx-deficient mouse, which serves 
as a model for the disease. Extracts made from primary 
astrocytes from normal mice were found to be proficient 
in repairing 5′-adenylated SSB substrates that resemble 
lesions produced by abortive ligation at oxidative break 
sites, whereas extracts from Aptx-deficient astrocytes 
were incapable of deadenylation and subsequent repair 
(Ahel et al., 2006). The DNA-adenylase activity revealed 
with human Aprataxin is also exhibited by its yeast 
homolog, Hnt3, but not by any other yeast HIT super-
family protein such as Hnt1, Hnt2, Apa1, and Apa2. It 
appears that the Aprataxins, which are conserved from 
yeast to man, have evolved to form a distinct branch of 
the HIT superfamily, where they have adopted a proof-
reading role in DNA repair (Figure S1).
Presently, there are no detailed studies of the catalytic 
mechanism of DNA deadenylation. However, Aprataxin 
activity is metal independent, and the central histidine 
of the HφHφHφφ sequence (φ represents a hydrophobic 
residue) (Figure 1), H260 in the case of human Aprataxin, 
is likely to provide the nucleophilic side chain for attack 
of the DNA 5′ phosphorus atom in order to break the 
5′-5′ phosphoanhydride bond between the AMP and 
the DNA leaving group. The resulting Aprataxin-AMP 
intermediate would be resolved by hydrolysis to release 
AMP and restore the enzyme in a second reaction step. 
By analogy with the mechanism proposed for other HIT 
superfamily proteins (Brenner, 2002), the two steps in 
this reaction may involve general acid-base chemistry that facilitates the disposal of the DNA leaving group and 
activates a water molecule for hydrolysis.
Recently, it was reported that Aprataxin also exhibits 
activities that remove 3′ phosphates and 3′ phosphogly-
colates from DNA ends (Takahashi et al., 2007). However, 
APE1 and PNKP are believed to remove such lesions in 
vivo, and these results need further substantiation.
The Zinc-Finger Domain Is Required for Aprataxin 
Activity
In retrospect, it is surprising that it took so long to uncover 
a role for Aprataxin as a DNA-specific adenylase. The 
presence of the N-terminal XRCC1/XRCC4-interacting 
FHA domain and the C-terminal ZnF domain provided 
significant clues to its actions on DNA. Recent studies 
have shown that Aprataxin binds both double- and sin-
gle-stranded DNA, in reactions dependent upon the ZnF 
motif (Kijas et al., 2006). Moreover, the protein exhibits 
a high affinity for adenylated rather than nonadenylated 
DNA, and specific complex formation is again depen-
dent upon the zinc-coordinating cysteines C319 and 
C322 (Rass et al., 2007). It is likely that Aprataxin uses 
its general DNA-binding capacity to scan the genome, 
such that the HIT and ZnF domains may then cooperate 
to form a high-affinity complex that locks the enzyme 
onto adenylated DNA lesions. Consistent with this pro-
posal, the DNA adenylase activity is reduced ?100-fold 
by mutation of the ZnF motif (Rass et al., 2007). The criti-
cal role that the ZnF plays in substrate recognition may 
explain why mutations that map to the C-terminal side of 
the catalytic HIT domain confer an AOA1 phenotype that 
is similar in severity to that caused by mutations within 
the HIT domain (Moreira et al., 2001).
Assessment of the Cellular Functions of Aprataxin
Cell lines derived from individuals with AOA1 are mildly 
sensitive to methyl methane sulfonate and hydrogen per-
oxide (Clements et al., 2004; Gueven et al., 2004). Con-
sistent with such a mild phenotype, no gross defects in 
SSB repair have been observed. There are, however, 
subtle changes that support the concept that Aprataxin 
is involved in SSB repair. First, cells derived from AOA1 
patients accumulate DNA breaks in the first few hours 
after camptothecin treatment (a drug that causes ssDNA 
breaks by inhibiting topoisomerase I) (Mosesso et al., 
2005), and second, downregulation of glutathione in 
Aprataxin-deficient cells, resulting in increased oxidative 
stress, led to the accumulation of SSBs and decreased 
cell survival when compared to control cells (Hirano et 
al., 2007). There are also reports that Aprataxin-defi-
cient cells show a greater number of induced chromo-
somal aberrations than control cells after camptothecin 
and hydrogen peroxide treatment (Gueven et al., 2004; 
Mosesso et al., 2005).
Under normal circumstances, Aprataxin is distrib-
uted throughout the nucleus. However, in response to 
the introduction of heavy-ion radiation-induced DNA 
damage, Aprataxin rapidly accumulates at damaged 
sites, where it colocalizes with XRCC1 (Gueven et al., 
2004). Similarly, Aprataxin is recruited to tracks of UV Cell 130, September 21, 2007 ©2007 Elsevier Inc. 997
laser-induced SSBs in mammalian cells grown in cul-
ture, in reactions dependent upon XRCC1 (Hirano et 
al., 2007). The interplay of Aprataxin and XRCC1, at 
sites where radiation-induced lesions are to be found, 
is consistent with a proofreading function in DNA-break 
repair events. It is likely, however, that Aprataxin is 
required for a fraction of the cellular SSB repair events 
but not for all SSB repair. The proofreading function of 998 Cell 130, September 21, 2007 ©2007 Elsevier Inc.Aprataxin may be necessary whenever a DNA ligase 
has attempted to ligate nicks that contain unconven-
tional DNA termini (Rass et al., 2007). In contrast, the 
effect of losing a primary SSB repair function is better 
exemplified by XRCC1, whose absence renders cells 
severely sensitive to camptothecin and other SSB-
inducing agents. Similarly, although Aprataxin has 
been implicated in nonhomologous end joining by its 
association with XRCC4/DNA ligase IV and removes 5′ 
adenylates present at DSBs in vitro (Rass et al., 2007), 
subtle repair defects present in Aprataxin-deficient 
cells may not be revealed against a background of 
highly cytotoxic DSBs.
TDP1 and SCAN1
Like AOA1, SCAN1 is a disorder that is targeted almost 
exclusively to the nervous system and is characterized 
by cerebellar ataxia, axonal sensorimotor neuropathy, 
hypercholesterolemia, and hypoalbuminemia. The dis-
ease is linked to chromosome region 14q31 and specifi-
cally to the TDP1 gene encoding tyrosyl-DNA phospho-
diesterase 1 (Takashima et al., 2002).
TDP1 is a member of the phospholipase D superfam-
ily and is involved in repairing covalent topoisomerase 
I-DNA adducts from abortive topoisomerase I (TopoI) 
reactions (Davies et al., 2002b; Interthal et al., 2001; 
Pouliot et al., 1999; Yang et al., 1996). The actions of 
TopoI relieve torsional stress that builds up during DNA 
metabolic processes such as replication, transcription, 
and chromatin condensation. This is achieved by tran-
siently breaking one DNA strand, to permit the rotation of 
the double helix around the intact strand. Strand break-
age is brought about by nucleophilic attack of a tyro-
sine residue in TopoI’s active site on a phosphodiester 
bond located in the DNA backbone (Figure 4). A trans-
esterification reaction then results in the linkage of the 
active site tyrosine to the 3′ terminus of the topoisom-
erase-induced nick. The enzyme-DNA complex, termed 
TopoI cleavage complex, remains intact for the duration 
of strand opening, before the 5′ hydroxyl is positioned 
for attack on the tyrosine-DNA phosphodiester bond to 
Figure 4. Resolution of Abortive TopoI Cleavage Complexes 
by TDP1
(Inset) Human TopoI relaxes DNA by breaking one DNA strand (1) to 
allow DNA rotation of the double helix around the intact strand. The 
transient TopoI cleavage complex between the enzyme and the DNA 
is resolved when TopoI catalyzes attack of the 5′ hydroxyl onto the 
active site tyrosine-DNA phosphodiester bond (2).
(Top panel) If the 5′ hydroxyl is unavailable for attack on the active site, 
for example due to misalignment caused by proximal DNA lesions, 
this catalytic cycle can be aborted leading to trapped, dead-end TopoI 
cleavage complexes. Trapped TopoI molecules are subjected to pro-
teolytic degradation, leaving a small peptide linked to the 3′ end of the 
SSB, referred to as 3′ tyrosyl.
(Lower panel) TDP1 resolves 3′-tyrosyl DNA lesions by a two-step 
mechanism: (1) nucleophilic attack at the DNA 3′ phosphate to release 
the TopoI peptide, and (2) hydrolysis of the transient linkage between 
TDP1 and the DNA substrate. After 3′-tyrosyl removal, the SSB can 
be processed and ligated. The reaction mechanism is indicated (see 
text for detail). The tyrosine of TopoI peptide (blue) and histidine side 
chains of TDP1 (green) are indicated.
recreate the original DNA-backbone linkage. It is known 
that the proximity of endogenous DNA lesions such as 
DNA mismatches, DNA breaks, or abasic sites, disrupts 
this catalytic cycle, trapping TopoI in “dead-end” cleav-
age complexes (Pourquier et al., 1997a; Pourquier et al., 
1997b). Trapping is caused by displacement of the 5′-
hydroxyl terminus, which becomes unavailable for attack 
on the TopoI cleavage complex. Similarly, TopoI cleav-
age complexes can become unduly long lived due to 
the enhanced binding of TopoI to oxidative base lesions, 
as demonstrated for 8 oxoguanine (Lesher et al., 2002). 
Dead-end or long-lived TopoI cleavage complexes serve 
as the substrate for TDP1, following the proteolytic deg-
radation of the topoisomerase (Debéthune et al., 2002; 
Interthal et al., 2001).
TDP1 contains two signature HKD-related motifs 
(H263 K266 N283 and H493 K495 N519), both of 
which contribute conserved residues to form a sin-
gle active site (Davies et al., 2002b; Interthal et al., 
2001). A disease-associated SCAN1 mutation, found 
in a large Saudi Arabian family, has been shown to 
change histidine 493 to arginine. The reaction mecha-
nism is thought to involve the two steps indicated in 
Figure 4; first, H263 of the N-terminal HKD motif acts 
as a nucleophile that breaks the phosphodiester bond 
between the TopoI active site tyrosine and the DNA 
3′-phosphate. This reaction is facilitated by proton-
ation of the tyrosine by the H493 residue of the C-
terminal HKD motif, which acts as a general acid. The 
result is formation of a covalent bond between TDP1 
H263 and the DNA. Second, H493 acts as a general 
base to activate a water molecule for hydrolysis of the 
TDP1 H263-DNA linkage, thereby liberating the DNA 
and restoring the enzyme (Davies et al., 2002a, 2002b; 
Interthal et al., 2001; Raymond et al., 2004).
TDP1 is highly conserved in eukaryotes and exhib-
its a potent activity on dead-end TopoI cleavage 
complex analogs in vitro. The physiological role of 
this protein, however, has been difficult to define due 
to the presence of alternative path-
ways that can remove TopoI cleav-
age complexes. In yeast, for exam-
ple, mutations in TDP1 do not confer 
sensitivity to camptothecin (the trap-
ping of TopoI by DNA damage can be 
emulated by treating cells with this 
intercalating drug), as these cells 
are able to eliminate TopoI adducts 
using an arsenal of structure-specific 
nucleases such as Rad1-Rad10 and 
Mus81-Mms4 (Pommier, 2006). In contrast, human 
cells are hypersensitive to camptothecin, even when 
TDP1 is functional.
Recent results, however, have established a defined 
role for TDP1 in SSB repair in human cells. TDP1 was 
found to form a complex with XRCC1, PNKP, and DNA 
ligase III that can repair model SSB substrates with 
3′-tyrosyl termini (El-Khamisy et al., 2005). Removal of 
TopoI adducts by TDP1 produces a SSB with 3′-phos-
phate/5′-hydroxyl termini, which are subsequently 
repaired by PNKP, converting these ends to conven-
tional 3′-hydroxyl and 5′-phosphate termini that can be 
further processed. Important new insight into the physi-
ological role of TDP1 was provided by the observation 
that lymphoblastoid cells derived from SCAN1 patients 
accumulate camptothecin-induced SSBs (El-Khamisy 
et al., 2005). Even when the drug was removed, these 
breaks remained unrepaired. Most importantly, it was 
possible to isolate TopoI cleavage complexes from the 
DNA of camptothecin-treated lymphoblastoid cells from 
SCAN1 individuals (Miao et al., 2006).
SSB Repair Defects and Neuronal Specificity
Aprataxin and TDP1 and their associated diseases, AOA1 
and SCAN1, exhibit some striking similarities (Figure 5). 
Both enzymes catalyze the hydrolytic release of DNA 
end-blocking lesions, and it is believed that the accu-
mulation of these lesions in the absence of Aprataxin or 
TDP1 provides the basis for the neurodegeneration seen 
in AOA1 and SCAN1, respectively. Aprataxin and TDP1 
associate with the SSB repair machinery in stable repair 
complexes, and yet their activities are not required for the 
primary break recognition or repair reactions. Instead, 
they provide proofreading functions after DNA ligation or 
DNA relaxation events have been prematurely aborted. 
Therefore, the accumulation of 5′-DNA adenylates and 
3′-DNA TopoI adducts in the absence of Aprataxin and 
TDP1, respectively, is expected to be a slow process. 
Nonetheless, the requirement for these enzymes should 
Figure 5. Comparison between Neurode-
generative Disorders AOA1 and SCAN1
AOA1 and SCAN1 are caused by dysfunction of 
the enzymes Aprataxin and TDP1, respectively, 
which provide DNA end-processing activities in 
DNA SSB repair. Loss of these enzymatic activi-
ties leads to similar disease phenotypes.Cell 130, September 21, 2007 ©2007 Elsevier Inc. 999
not be limited to the nervous system—so why do neurons 
in particular succumb to these lesions? The answers may 
lie in a unique combination of tissue-specific characteris-
tics, which increase the requirement for Aprataxin/TDP1 
proofreading functions in neuronal tissues.
So what are these tissue-specific characteristics? 
First, neurons are terminally differentiated postmitotic 
cells. Due to the absence of DNA replication, unresolved 
5′ adenylates and/or 3′-TopoI adducts will slowly accu-
mulate at nicks over a period of years. In contrast, rep-
licating cells have other means to remove these lesions. 
For example, in cycling human cells, replication runoff 
can convert TopoI adducts into DSBs (Strumberg et al., 
2000), such that the lesion may subsequently be removed 
by exonucleases or the actions of a flap endonuclease 
in the presence of a DNA helicase (Figure 6B). The DSB 
can then be repaired by homologous recombination 
that will restore the replication fork. Similarly, in cycling 
Aprataxin-deficient cells, replication of DNA containing 
nicked 5′ adenylates will lead to DSB formation. In this 
case, the nucleases that promote 5′-3′ resection of the 
DSB to initiate homologous recombination are likely to 
remove the 5′-adenylate group (Figure 6A).
Figure 6. Alternative Mechanisms for the Removal of 5′ 
Adenylates and 3′-TopoI Adducts
(A and B) SSBs with end-blocking 5′ adenylates or 3′-TopoI adducts 
may be repaired in cells capable of DNA replication. Fork progression 
will convert persistent SSBs into DSBs that can be cleansed by the 
actions of nucleases (indicated by red arrows), possibly in combina-
tion with DNA helicases. The resultant DSBs will be repaired by ho-
mologous recombination to restart the replication fork. Nonreplicating 
cells will not be able to carry out these repair reactions.1000 Cell 130, September 21, 2007 ©2007 Elsevier Inc.The relative contributions of TDP1-dependent and 
TDP1-independent repair mechanisms for TopoI adducts 
are less clear in humans than in yeast. In contrast to 
tdp1 mutant yeast cells, cycling cells from individuals 
with SCAN1 are more camptothecin sensitive than con-
trol cells. These cells accumulate in S phase and initi-
ate apoptosis, indicating that TDP1-independent repair 
pathways in human cells are not as robust as they are 
in yeast (Interthal et al., 2005). However, some level of 
redundancy may allow cycling TDP1-deficient cells—and, 
by analogy, possibly also Aprataxin-deficient cells—to 
at least cope with low levels of physiological TopoI and 
adenylation adducts, respectively, whereas neuronal 
cells do not have this option. The absence of a genomic 
instability and cancer phenotype in AOA1 and SCAN1 
further supports the concept of a nuclease/homologous 
recombination-dependent backup pathway to cope with 
replication-dependent DSB-associated TopoI adducts 
and adenylated DSBs.
5′ adenylates may also be removed by “long patch 
repair” mechanisms in cycling Aprataxin-deficient cells. 
In this subpathway of base excision repair, a processive 
DNA polymerase creates a 5′ flap, which can subse-
quently be removed by the structure-specific endonu-
clease FEN1. However, long patch repair is active mainly 
during S phase and involves several factors abundant 
only during DNA replication (Fortini and Dogliotti, 2007). 
As a consequence, long patch repair may not be avail-
able in nonproliferating neuronal cells to bypass the 
requirement for Aprataxin.
Second, persistent 3′-TopoI adducts and 5′ adenyl-
ates at single-strand breaks in the genome would be 
expected to interfere with transcription. A number of 
studies indicate that the transcriptional demand is 
particularly high in neurons (Morris and Geller, 1996; 
Sarkander and Dulce, 1978), leading to the suggestion 
that the relative impact of blocking lesions will be more 
severe in neurons than in other cell types. A diverse tran-
scriptional requirement will also increase the frequency 
of TopoI adducts, as a collision with the transcriptional 
machinery provokes the conversion of transient to dead-
end TopoI cleavage complexes. Consistent with this, 
TDP1-deficient cells are unable to reverse a camptoth-
ecin-induced transcription block after drug removal (El-
Khamisy et al., 2005).
Blocked transcription not only deprives the cell of vital 
transcripts but may also induce apoptosis (Ljungman 
and Lane, 2004). Such transcriptional disturbances may 
also contribute to the neurodegeneration associated 
with nucleotide-excision repair disorders, as discussed 
earlier. Nucleotide excision repair comprises two sub-
pathways: (1) global genome repair, which is required 
for the surveillance of the genome at large, and (2) tran-
scription-coupled repair, which specifically removes 
lesions from transcriptionally active genes. Neurologi-
cal implications appear to be more intimately connected 
with defects in transcription-coupled repair, as exempli-
fied by CSA and CSB mutations.
Third, neurons are subjected to high levels of oxidative 
stress, as the brain consumes a disproportionately high 
amount of oxygen relative to other tissues. As a conse-
quence of the elevated levels of reactive oxygen species, 
neuronal cells accumulate higher than normal levels of 
oxidative DNA-base and -backbone damage, which in 
turn will trap TopoI in dead-end complexes. Similarly, 
reactive oxygen species-induced dirty breaks will trap 
DNA ligase III and lead to increased levels of DNA ade-
nylation. Therefore, high oxidative stress is believed to 
increase the dependency on the proofreading functions 
of TDP1 and Aprataxin in the nervous system.
Finally, and importantly, the nervous system has a 
very limited capacity for regeneration. Cell loss cannot 
be compensated by new growth but instead leads to the 
progressive loss of physiological functions. Combined 
with the intrinsic high oxidative stress and transcrip-
tional demand, and no alternative route for repair such 
as homologous recombination, we suggest that these 
factors are the key to further understanding of SCAN1, 
AOA1, and the neurological implications of other DNA 
repair-defective diseases.
Future Directions
The most straightforward way to correlate a molecu-
lar repair defect with a human disease phenotype is 
to directly isolate the unrepaired DNA lesion from the 
affected cell types. In this regard, DNA TopoI adducts 
were recently isolated from camptothecin-treated cells 
from SCAN1 individuals (Miao et al., 2006). It has not, 
however, been possible to isolate DNA adenylates from 
Aprataxin-deficient cells, and this may not be an easy 
task. The accumulation of DNA adenylates, to the point 
when they become problematic to cellular functions, is 
likely to be a process that takes several years. Although 
a mouse model for AOA1, which lacks Aprataxin, has 
been developed (Ahel et al., 2006), it is thought that 
the lifespan of these mice may be too short to allow the 
progressive accumulation of the lesion to levels that are 
measurable. The best option for adenylate detection 
might be the analysis of patient-derived materials.
In this review, we have detailed the concept that it 
is the accumulation of oxidative stress-induced DNA 
damage that underlies neurodegeneration in AOA1 and 
SCAN1 tissues. Cell death ensues as the transcriptional 
readout of the genome deteriorates. This sequence of 
events may not be unique to AOA1 and SCAN1 but could 
underlie neurological features in other human DNA repair-
related disorders. Indeed, unrepaired SSBs may play a 
more important role than originally thought in diseases 
linked to defects in DSB repair. In this regard, additional 
subtypes of AOA, such as AOA2, may also be due to 
defects in SSB repair. The AOA2 gene encodes Sena-
taxin, a putative RNA/DNA helicase (Chen et al., 2006). 
Recent studies have shown that AOA2 cells are sensitive 
to oxidative damage and exhibit chromosomal instabil-
ity following hydrogen peroxide treatment (Suraweera et 
al., 2007). A third subtype of AOA, called AOA3, has not yet been defined by a genetic locus but is characterized 
by a cellular sensitivity to induced SSBs (Gueven et al., 
2007a, 2007b).
In addition to defects in the repair of damage caused 
by reactive oxygen species, mutations in genes that 
directly influence the endogenous levels of reactive oxy-
gen species may also be linked to neuronal viability. For 
example, Friedreich’s ataxia, the most common heredi-
tary ataxia, is caused by an iron imbalance in mitochon-
dria (Wilson, 2003). Although the cellular role of Frataxin, 
the product of the disease-related gene, appears to be 
multifaceted, a specific function in iron detoxification and 
prevention of formation of reactive oxygen species gen-
erated by the Fenton reaction was recently established 
(Gakh et al., 2006). Freidreich’s ataxia is characterized 
by neurodegeneration, cardiomyopathy, and diabetes, 
and DNA damage induced by reactive oxygen species 
may be intimately linked to the neurological implications. 
One question for the future will be to determine whether 
limiting oxidative stress by antioxidant treatment with 
coenzyme Q10 and vitamin E derivatives has the poten-
tial to alleviate the neurological defects in this disease 
and others that result from oxidative DNA damage.
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